Schroder Investment Management Group trimmed its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 91.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 38,109 shares of the company’s stock after selling 405,237 shares during the quarter. Schroder Investment Management Group owned 0.09% of Meridian Bioscience worth $541,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC grew its position in Meridian Bioscience by 19.2% during the second quarter. Parametric Portfolio Associates LLC now owns 191,114 shares of the company’s stock worth $3,010,000 after buying an additional 30,838 shares in the last quarter. Prudential Financial Inc. boosted its holdings in Meridian Bioscience by 280.6% during the 2nd quarter. Prudential Financial Inc. now owns 273,330 shares of the company’s stock valued at $4,305,000 after acquiring an additional 201,519 shares during the period. Russell Investments Group Ltd. raised its position in Meridian Bioscience by 29.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 39,672 shares of the company’s stock valued at $625,000 after purchasing an additional 8,954 shares during the last quarter. Aperio Group LLC raised its position in Meridian Bioscience by 40.0% during the 2nd quarter. Aperio Group LLC now owns 51,385 shares of the company’s stock valued at $809,000 after purchasing an additional 14,682 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. raised its position in Meridian Bioscience by 55.3% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 87,401 shares of the company’s stock valued at $1,250,000 after purchasing an additional 31,140 shares during the last quarter. Institutional investors own 87.01% of the company’s stock.

Meridian Bioscience Inc. (VIVO) opened at $14.25 on Friday. Meridian Bioscience Inc. has a 52-week low of $10.75 and a 52-week high of $18.20. The company has a debt-to-equity ratio of 0.30, a quick ratio of 4.04 and a current ratio of 5.85. The firm has a market capitalization of $632.66, a P/E ratio of 19.93 and a beta of 0.89.

Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings data on Thursday, November 9th. The company reported $0.15 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.15. Meridian Bioscience had a return on equity of 17.03% and a net margin of 10.74%. The company had revenue of $49.70 million during the quarter, compared to analyst estimates of $48.28 million. During the same quarter last year, the company earned $0.14 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. equities analysts forecast that Meridian Bioscience Inc. will post 0.66 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Monday, November 20th were paid a dividend of $0.125 per share. The ex-dividend date was Friday, November 17th. This represents a $0.50 annualized dividend and a yield of 3.51%. Meridian Bioscience’s dividend payout ratio is 98.04%.

Several research analysts have recently issued reports on the company. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Friday, November 17th. Canaccord Genuity reissued a “hold” rating and issued a $14.00 target price on shares of Meridian Bioscience in a research report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Meridian Bioscience currently has a consensus rating of “Hold” and a consensus price target of $11.50.

TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/schroder-investment-management-group-lowers-holdings-in-meridian-bioscience-inc-vivo/1769364.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.